Position in NAMS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$708,470
+$66,126 QoQ
Shares Held
20,905
+4.2% QoQ
Ownership
0.017%
of shares outstanding
% of Portfolio
0.16%
of 13F equity value
Holder Rank
#118
of 198 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NAMS Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026HighVista Strategies LLC holds $278,365,756 across 70 Biotechnology names. NAMS ranks #65 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABVX |
Abivax S.A.
|
113,031 | $15,062,511 | |
| 2 | RVMD |
Revolution Medicines, Inc.
|
66,983 | $12,544,576 | |
| 3 | DFTX |
Definium Therapeutics, Inc.
|
242,884 | $11,425,263 | |
| 4 | IMVT |
Immunovant, Inc.
|
277,873 | $10,706,446 | |
| 5 | PRAX |
Praxis Precision Medicines, Inc.
|
30,210 | $10,114,005 | |
| 6 | RLAY |
Relay Therapeutics, Inc.
|
506,235 | $9,471,656 | |
| 7 | PCVX |
Vaxcyte, Inc.
|
149,739 | $8,704,328 | |
| 8 | TNGX |
Tango Therapeutics, Inc.
|
260,070 | $8,129,788 |
All Filings in NAMS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $708,470 | 20,905 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $642,344 | 20,067 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $1,248,356 | 35,586 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $905,273 | 31,831 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $349,052 | 19,274 | Shares | Sole | 2025-08-14 | |
| No filing history on record for this holder in this stock. | ||||||